busulfan has been researched along with Astrocytoma, Grade IV in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The current study was designed to evaluate the toxicity and activity of Spartaject Busulfan, a microcrystalline preparation of busulfan, following its intrathecal administration into a nude rat model of human neoplastic meningitis." | 7.70 | Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. ( Archer, GE; Bigner, DD; Colvin, OM; Friedman, AH; Friedman, HS; Fuchs, HE; McCullough, W; McLendon, RE; Rose, M; Sampson, JH; Sands, H, 1999) |
| "Busulfan is an alkylating agent commonly used in the treatment of chronic myelogenous leukemia and in combination with cyclophosphamide in preparation for allogeneic bone marrow transplantation." | 5.30 | Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. ( Ali-Osman, F; Bigner, DD; Colvin, OM; Elion, GB; Friedman, HS; Griffith, OW; Hare, CB; Keir, S; Marcelli, SL; Petros, WP, 1997) |
| " Our aim was to compare non-myeloablative busulfan conditioning against head-shielded irradiation bone marrow chimeras prior to implantation of glioblastoma, a malignant brain tumour with a pro-inflammatory phenotype." | 3.91 | Non-myeloablative busulfan chimeric mouse models are less pro-inflammatory than head-shielded irradiation for studying immune cell interactions in brain tumours. ( Bigger, BW; Forte, G; Kamaly-Asl, ID; Liao, A; O'Leary, C; Parker, H; Rowlston, S; Telfer, B; Williams, K; Youshani, AS, 2019) |
| "The current study was designed to evaluate the toxicity and activity of Spartaject Busulfan, a microcrystalline preparation of busulfan, following its intrathecal administration into a nude rat model of human neoplastic meningitis." | 3.70 | Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. ( Archer, GE; Bigner, DD; Colvin, OM; Friedman, AH; Friedman, HS; Fuchs, HE; McCullough, W; McLendon, RE; Rose, M; Sampson, JH; Sands, H, 1999) |
| "Busulfan is an alkylating agent commonly used in the treatment of chronic myelogenous leukemia and in combination with cyclophosphamide in preparation for allogeneic bone marrow transplantation." | 1.30 | Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. ( Ali-Osman, F; Bigner, DD; Colvin, OM; Elion, GB; Friedman, HS; Griffith, OW; Hare, CB; Keir, S; Marcelli, SL; Petros, WP, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Youshani, AS | 1 |
| Rowlston, S | 1 |
| O'Leary, C | 1 |
| Forte, G | 1 |
| Parker, H | 1 |
| Liao, A | 1 |
| Telfer, B | 1 |
| Williams, K | 1 |
| Kamaly-Asl, ID | 1 |
| Bigger, BW | 1 |
| Wick, W | 2 |
| Hermisson, M | 1 |
| Kortmann, RD | 1 |
| Küker, WM | 1 |
| Duffner, F | 1 |
| Dichgans, J | 2 |
| Bamberg, M | 1 |
| Weller, M | 2 |
| Graham, ML | 1 |
| Herndon, JE | 1 |
| Casey, JR | 1 |
| Chaffee, S | 1 |
| Ciocci, GH | 1 |
| Krischer, JP | 1 |
| Kurtzberg, J | 1 |
| Laughlin, MJ | 1 |
| Longee, DC | 1 |
| Olson, JF | 1 |
| Paleologus, N | 1 |
| Pennington, CN | 1 |
| Friedman, HS | 3 |
| Hare, CB | 1 |
| Elion, GB | 1 |
| Colvin, OM | 2 |
| Ali-Osman, F | 1 |
| Griffith, OW | 1 |
| Petros, WP | 1 |
| Keir, S | 1 |
| Marcelli, SL | 1 |
| Bigner, DD | 2 |
| Archer, GE | 1 |
| Sampson, JH | 1 |
| McLendon, RE | 1 |
| Friedman, AH | 1 |
| Rose, M | 1 |
| Sands, H | 1 |
| McCullough, W | 1 |
| Fuchs, HE | 1 |
| Schmidt, F | 1 |
| Herrlinger, U | 1 |
| Mungyerová, G | 1 |
| Jacz, K | 1 |
| Kuzma, I | 1 |
| Babusiková, O | 1 |
| Kalafut, F | 1 |
3 trials available for busulfan and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Bu | 2002 |
Treosulfan chemotherapy for recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marrow; Brain Neoplasms; Busulfan; | 2000 |
Experiences with malignant brain tumours in clinic and in tissue culture.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Arsenicals; Astrocytoma; Brain Neoplasms; Busulfan; Clin | 1965 |
4 other studies available for busulfan and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Non-myeloablative busulfan chimeric mouse models are less pro-inflammatory than head-shielded irradiation for studying immune cell interactions in brain tumours.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Brain Neoplasms; Busulfan; Cell Line, | 2019 |
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brai | 1997 |
Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Southern; Busulfan; Drug Resistance, Neoplasm; | 1997 |
Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Busulfan; Drug Administration Schedule; Female; Glioblas | 1999 |